NovaBridge Biosciences (NBP) Non-Current Deferred Tax Liability (2017 - 2022)

NovaBridge Biosciences (NBP) has 4 years of Non-Current Deferred Tax Liability data on file, last reported at $2.5 million in Q4 2022.

• Quarterly Non-Current Deferred Tax Liability fell 10.69% year-over-year to $2.5 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $2.5 million (down 10.69% YoY) and the FY2022 annual result came in at $2.6 million, down 7.93% from the prior year.
• Non-Current Deferred Tax Liability retreated to $2.5 million in Q4 2022 per NBP's latest filing, from $2.8 million in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $5.4 million in Q4 2018 and bottomed at $2.5 million in Q4 2022.
• The 3-year median for Non-Current Deferred Tax Liability is $2.8 million (2021), against an average of $3.6 million.
• The widest annual swing landed in 2018, when Non-Current Deferred Tax Liability retreated 4.31%; it then dropped 10.69% in 2022.
• Tracing NBP's Non-Current Deferred Tax Liability over 3 years: stood at $5.4 million in 2018, then slumped by 47.83% to $2.8 million in 2021, then retreated by 10.69% to $2.5 million in 2022.
• Per Business Quant, the three latest NBP Non-Current Deferred Tax Liability figures stand at $2.5 million (Q4 2022), $2.8 million (Q4 2021), and $5.4 million (Q4 2018).

Peer Comparison